13 Results for "

tumor retention agent

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "tumor retention agent" in MCE Product Catalog:

Cat. No.: HY-16496
CAS No.: 26599-17-7
Synonyms: OSI-7836
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Thiarabine (OSI-7836) is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies .
loading...
    loading...
Cat. No.: HY-164725
CAS No.: 3023869-94-2
Research Areas:  

Cancer

FAPI-mFS is a selective fibroblast activation protein (FAP) inhibitor with an IC50 of 0.0014 μM against human FAP. Through its covalent binding property with FAP, FAPI-mFS enhances its uptake and retention time in cancer cells. When radiolabeled with 68Ga, FAPI-mFS serves as a PET/CT imaging agent with superior tumor-to-background tissue contrast and lesion detection capability. When radiolabeled with 177Lu or 225Ac, FAPI-mFS induces tumor regression and inhibition in preclinical models. FAPI-mFS can be used in studies related to cancer and radionuclide-conjugated drugs (RDC) .
loading...
    loading...
Cat. No.: HY-170779
CAS No.: 3078291-78-5
Target:  

FAP

Research Areas:  

Cancer

DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .
loading...
    loading...
Cat. No.: HY-159176
CAS No.: 2775428-94-7
Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC50s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues .
loading...
    loading...
Cat. No.: HY-170842
Target:  

Apoptosis

Research Areas:  

Cancer

TDK-HCPT is a small-molecule conjugate that links glutathione-sensitive thiamine disulfide to the chemotherapy drug 10-Hydroxycamptothecin (HY-N0095) via a thioketal bond. TDK-HCPT can target tumor cells and prolong the retention of chemotherapy agents within tumor cells. TDK-HCPT can inhibit tumor growth, induce apoptosis of tumor cells, and has anti-tumor activity .
loading...
    loading...
Cat. No.: HY-171331
CAS No.: 2416165-76-7
Target:  

PD-1/PD-L1 Integrin

Research Areas:  

Cancer

AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 + T cells .
loading...
    loading...
Cat. No.: HY-116604
CAS No.: 4425-23-4
Synonyms: PD 139530
Target:  

PI3K Akt

Research Areas:  

Cancer

RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .
loading...
    loading...
Cat. No.: HY-116604A
CAS No.: 21314-60-3
Synonyms: PD 139530 hydrochloride
Target:  

PI3K Akt

Research Areas:  

Cancer

RLX (PD 139530) hydrochloride is the hydrochloride of RLX (HY-116604). RLX is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .
loading...
    loading...
Cat. No.: HY-P11591
CAS No.: 3110124-60-9
Synonyms: PSMA-DOTA-PEI2
Research Areas:  

Cancer

PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer .
loading...
    loading...
Cat. No.: HY-182387
CAS No.: 208986-26-9
Research Areas:  

Cancer

NM404 is a targeted radionuclide processing agent with slow clearance. Radioiodine-labeled NM404 is a small-molecule phospholipid ether analog that exhibits significant tumor uptake capacity and persistent tumor retention properties in more than 45 spontaneous and xenograft tumor models .
loading...
    loading...
Cat. No.: HY-16496A
CAS No.: 1060763-87-2
Synonyms: OSI-7836 hydrochloride
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Thiarabine (OSI-7836) hydrochloride is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine hydrochloride is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine hydrochloride is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies .
loading...
    loading...
Cat. No.: HY-181494
CAS No.: 3056070-96-0
Target:  

FAP

Research Areas:  

Cancer

FAPI-X5 is a fibroblast activation protein (FAP) inhibitor. FAPI-X5 binds to the FAP catalytic domain, forming hydrogen bonds with key active residues and engaging in π-π stacking to drive functional inhibition. FAPI-X5 exhibits albumin binding activity to prolong systemic circulation half-life. FAPI-X5 induces cytostatic effects on glioblastoma tumors, slowing tumor growth without regression. FAPI-X5, when labeled with 68Ga, acts as a PET tracer with rapid tumor uptake and high-contrast imaging in glioblastoma tumor-bearing mice. FAPI-X5, when labeled with 177Lu or 47Sc, functions as a targeted radionuclide agent with prolonged tumor retention. FAPI-X5 can be used for the research of glioblastoma .
loading...
    loading...
Cat. No.: HY-181580
Target:  

FAP

Research Areas:  

Cancer

FAP Ligand 3 is a FAP ligand with a Ki value of 0.092 nM. FAP Ligand 3 acts as a tumor-retaining agent and serves as a FAP-targeted positron emission tomography (PET) tracer for tumor imaging. FAP Ligand 3 is applicable to studies related to glioma .
loading...
    loading...
  • 1